Welcome to our dedicated page for Tempest Therapeutics SEC filings (Ticker: TPST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Even seasoned biotech analysts can lose hours hunting for R&D burn rates or trial updates buried inside Tempest Therapeutics annual report 10-K simplified. The company’s filings span complex immuno-oncology science, cash-flow projections, and clinical data tables—making it hard to spot what really moves TPST’s valuation. If you have ever searched “Tempest Therapeutics SEC filings explained simply,” you already know the challenge.
Stock Titan solves it. Our AI-powered summaries turn a 300-page disclosure into a few clear insights, so understanding Tempest Therapeutics SEC documents with AI becomes routine. Get instant alerts on Tempest Therapeutics Form 4 insider transactions real-time, review each Tempest Therapeutics quarterly earnings report 10-Q filing with side-by-side trend charts, and dive into Tempest Therapeutics 8-K material events explained the moment trial data or financing news hits EDGAR. We also connect the dots between pipeline milestones and numbers, delivering Tempest Therapeutics earnings report filing analysis that highlights runway, partnership revenue, and study costs.
Need to monitor leadership confidence? Track Tempest Therapeutics insider trading Form 4 transactions or drill into Tempest Therapeutics executive stock transactions Form 4. Curious about pay structures? The Tempest Therapeutics proxy statement executive compensation section breaks down equity grants for the scientific leadership team. Whether you are evaluating dilution risk, following immuno-oncology catalysts, or comparing quarter-over-quarter spend, our comprehensive coverage—with real-time feeds for every form type—keeps critical disclosures one click away.
Tempest Therapeutics (TPST) filed its Q3 2025 report, highlighting constrained liquidity and a strategic review. Cash and cash equivalents were
Quarterly net loss was
Financing actions included a registered direct offering delivering net proceeds of
Tempest Therapeutics (TPST) furnished an 8-K under Item 2.02 announcing it issued a press release with financial results for the quarter ended September 30, 2025 and other business highlights. The press release is attached as Exhibit 99.1 and incorporated by reference. The information is furnished, not filed, under the Exchange Act.
The filing also includes Exhibit 104, the cover page interactive data file embedded within the Inline XBRL document.
Versant-affiliated funds filed Amendment No.6 to their Schedule 13D for Tempest Therapeutics (TPST) to update reported holdings after the issuer sold additional shares, causing dilution. The Amendment lists holdings including 162,972 shares (3.7%) held by Versant Vantage II, 90,084 shares (2.0%) held by Versant Venture Capital IV, 16,149 shares (0.4%) held by Versant Venture Capital VI, and 567 shares (0.0%) held by Versant Side Fund IV, with percentages based on 4,440,161 shares outstanding as of August 4, 2025.
The filing notes a one-for-thirteen reverse stock split effective April 8, 2025, states the aggregate ownership reported by the Reporting Persons decreased by over 1% due to the Issuer's additional share sales, and expressly disclaims status as a "group".
Tempest Therapeutics is a clinical-stage oncology company advancing two lead programs while conducting a strategic review to extend limited cash resources. The lead candidate, amezalpat, is positioned to begin a pivotal Phase 3 trial in first-line hepatocellular carcinoma and has received regulatory momentum including FDA Orphan Drug and Fast Track designations, a favorable end-of-Phase 2 meeting, and agency clearances to proceed in the U.S. and China; the company also reported EMA Orphan Drug designation. The second program, TPST-1495, received FDA authorization for an NCI-supported Phase 2 study in FAP and an FDA Orphan Drug designation.
Financially, Tempest reported $14.3 million in cash and cash equivalents and an accumulated deficit of $225.8 million. Net loss was $18.7 million for the six months ended June 30, 2025. The company expects existing cash to fund operations for less than 12 months, raising substantial doubt about its ability to continue as a going concern. In April 2025 Tempest launched a strategic alternatives process, reduced headcount (21 of 26 employees), transitioned key executives to consulting arrangements, completed a registered direct offering that raised net proceeds of ~$4.1 million, sold ~$2.8 million of stock via its ATM program year-to-date, and repaid its term loan in April 2025.
Tempest Therapeutics reported that it has issued a press release announcing its financial results for the quarter ended June 30, 2025. The press release is attached to this report as Exhibit 99.1. This Form 8-K indicates the company is furnishing the press release rather than "filing" it, meaning the release is provided for investor information in this report but is not subject to the liabilities of being formally filed or automatically incorporated by reference in other Securities Act filings. The 8-K itself does not include the numerical financial statements; those figures are contained in the attached press release.
FAQ
What is the current stock price of Tempest Therapeutics (TPST)?
What is the market cap of Tempest Therapeutics (TPST)?
